Compare Skyworks Solutions Inc (SWKS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs Tango Therapeutics Inc. — how do they compare? Skyworks Solutions Inc trades at $76.44 (market cap $18.08B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Skyworks Solutions Inc is far larger — about 4.8× Tango Therapeutics Inc.'s market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and Tango Therapeutics Inc. for 0 Days on average.
| SWKS | TNGX | |
|---|---|---|
Market Cap | $18.08B | $3.74B |
Volume | 5,128,915 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $91.45 | $32.90 |
52-Week Low | $52.50 | $7.50 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $17.96B | $2.76B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $76.56, up 2.49% with a bearish technical signal despite recent earnings beats. The stock shows declining revenue and profit margins over recent years but maintains strong analyst support with 60% buy ratings. The pending Qorvo merger represents a significant catalyst, with regulatory clearances obtained and potential for $500 million in synergies. Current valuation metrics include a P/E of 39.68 and P/S of 2.87.
The merger with Qorvo offers substantial growth potential through expanded scale and market diversification, though integration risks and declining financial metrics warrant caution. With the current price below the $79.70 consensus target, upside exists if merger benefits materialize, but investors face execution risk and competitive pressures in the semiconductor sector.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
